Dabrafenib plus trametinib vs encorafenib plus binimetinib in <i>BRAF</i> -mutant metastatic melanoma: a real-world propensity score–matched survival analysis
We found no evidence that encorafenib plus binimetinib is superior to dabrafenib plus trametinib in metastatic melanoma. These findings suggest that the choice between these combinations should be guided by tolerability profiles and economic considerations rather than efficacy.
Authors
- A.A. Luczak
- Louise Mahncke Guldbrandt
- Marco Donia (ORCID: https://orcid.org/0000-0003-4966-9752)
- Eva Ellebæk (ORCID: https://orcid.org/0000-0001-6748-9232)
- Christina H. Bruvik Ruhlmann (ORCID: https://orcid.org/0000-0002-3728-273X)
- Yago Garitaonaindía (ORCID: https://orcid.org/0000-0002-7816-3294)
- Troels Holz Borch (ORCID: https://orcid.org/0000-0002-4402-9281)
- Rasmus Blechingberg Friis (ORCID: https://orcid.org/0000-0002-0564-146X)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Lars Bastholt (ORCID: https://orcid.org/0000-0001-5478-9826)
- Henrik Schmidt (ORCID: https://orcid.org/0000-0002-4063-3561)
- Shawez Khan (ORCID: https://orcid.org/0000-0003-1682-4824)
Institutions
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
- Aalborg University (DK)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1093/jnci/djaf263
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00